Hidetsugu Fujigaki

Prof. Dr. Hidetsugu Fujigaki


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Neurochemistry International
Verified
Journal Article
Closed access
HFHidetsugu Fujigaki
Hidetsugu Fujigaki
AMAkihiro Mouri
Akihiro Mouri
YYYasuko Yamamoto
Yasuko Yamamoto
TNToshitaka Nabeshima
Toshitaka Nabeshima
KSKuniaki Saito
Kuniaki Saito

15 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YYYukihiro Yoshida
Yukihiro Yoshida
HFHidetsugu Fujigaki
Hidetsugu Fujigaki
KKKoichi Kato
Koichi Kato
KYKyoka Yamazaki
Kyoka Yamazaki
SFSuwako Fujigaki
Suwako Fujigaki
KSKuniaki Saito
Kuniaki Saito
The enzyme kynurenine aminotransferase (KAT) catalyses the conversion of kynurenine (KYN) to kynurenic acid (KYNA). Although the isozymes KAT1–4 have been identified, KYNA is mainly produced by KAT2 in brain tissues. KNYA is an antagonist of N-methyl-D-aspartate and α-7-nicotinic acetylcholine receptors, and accumulation of KYNA in the brain has been associated with the pathology of schizophrenia. Therefore, KAT2 could be exploited as a therapeutic target for the management of schizophrenia. Although currently available KAT2 inhibitors irreversibly bind to pyridoxal 5′-phosphate (PLP), inhibition via this mechanism may cause adverse side effects because of the presence of other PLP-dependent enzymes. Therefore, we identified novel selective KAT2 inhibitors by screening approximately 13,000 molecules. Among these, glycyrrhizic acid (GL) and its analogues, glycyrrhetinic acid (GA) and carbenoxolone (CBX), were identified as KAT2 inhibitors. These compounds were highly selective for KAT2 and competed with its substrate KYN, but had no effects on the other 3 KAT isozymes. Furthermore, we demonstrated that in complex structures that were predicted in docking calculations, GL, GA and CBX were located on the same surface as the aromatic ring of KYN. These results indicate that GL and its analogues are highly selective and competitive inhibitors of KAT2.

24 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HNHiroyuki Naruse
Hiroyuki Naruse
HIHiroyasu Ito
Hiroyasu Ito
HIHideo Izawa
Hideo Izawa
MSMasayoshi Sarai
Masayoshi Sarai
JIJunnichi Ishii
Junnichi Ishii
KSKuniaki Saito
Kuniaki Saito
Concern has been raised about the effectiveness of the coronavirus disease 2019 (COVID-19) vaccine in the population of patients with various comorbidities such as heart disease. We investigated the humoral response to the BNT162b2 mRNA COVID-19 vaccine in patients with cardiovascular disease (CVD). We measured IgG against severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain (RBD-IgG) in 85 CVD patients and 179 healthcare workers (HCWs). Blood samples were collected from patients and HCWs three times: (1) before the first dose of vaccination, (2) two weeks after the first dose of vaccination, and (3) two weeks after the second dose of vaccination. Patients with CVD showed a significantly inferior serological response to the BNT162b2 mRNA COVID-19 vaccine at 14 days after the prime dose compared to HCWs (21% vs. 95%, p < 0.001). Median RBD-IgG titers of patients with CVD at 14 days after the second dose were significantly lower than those of HCWs (137.2 U/mL (80.6–200.4 U/mL) vs. 176.2 U/mL (123.9–260.0 U/mL), p < 0.001). In multivariable analyses, CVD is significantly associated with seropositivity after first vaccination and RBD-IgG titers after second vaccination. CVD patients may have a poor humoral response to the BNT162b2 mRNA COVID-19 vaccine, need to be closely monitored, and require earlier revaccination to ensure stronger immunity and protection against infection.

23 February 2022 in Microbiology Spectrum
Verified
Journal Article
Open access
HFHidetsugu Fujigaki
Hidetsugu Fujigaki
YYYasuko Yamamoto
Yasuko Yamamoto
TKTakenao Koseki
Takenao Koseki
SBSumi Banno
Sumi Banno
TATatsuya Ando
Tatsuya Ando
KSKuniaki Saito
Kuniaki Saito
Mass vaccination campaigns using mRNA vaccines against SARS-CoV-2 have begun in many countries. Serological assays to detect antibody production may be a useful tool to monitor the efficacy of SARS-CoV-2 vaccination in individuals.

15 May 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
HFHidetsugu Fujigaki
Hidetsugu Fujigaki
MIMasato Inaba
Masato Inaba
MOMichiko Osawa
Michiko Osawa
SMSaya Moriyama
Saya Moriyama
YTYoshimasa Takahashi
Yoshimasa Takahashi
KSKuniaki Saito
Kuniaki Saito
Serological tests for detection of anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Abs in blood are expected to identify individuals who have acquired immunity against SARS-CoV-2 and indication of seroprevalence of SARS-CoV-2 infection. Many serological tests have been developed to detect Abs against SARS-CoV-2. However, these tests have considerable variations in their specificity and sensitivity, and whether they can predict levels of neutralizing activity is yet to be determined. This study aimed to investigate the kinetics and neutralizing activity of various Ag-specific Ab isotypes against SARS-CoV-2 in serum of coronavirus disease 2019 (COVID-19) patients confirmed via PCR test. We developed IgG, IgM, and IgA measurement assays for each Ag, including receptor-binding domain (RBD) of spike (S) protein, S1 domain, full-length S protein, S trimer, and nucleocapsid (N) domain, based on ELISA. The assays of the S protein for all isotypes showed high specificity, whereas the assays for all isotypes against N protein showed lower specificity. The sensitivity of all Ag-specific Ab isotypes depended on the timing of the serum collection and all of them, except for IgM against N protein, reached more than 90% at 15–21 d postsymptom onset. The best correlation with virus-neutralizing activity was found for IgG against RBD, and levels of IgG against RBD in sera from four patients with severe COVID-19 increased concordantly with neutralizing activity. Our results provide valuable information regarding the selection of serological test for seroprevalence and vaccine evaluation studies.

1 September 2020 in Heliyon
Verified
Journal Article
Open access
HFHidetsugu Fujigaki
Hidetsugu Fujigaki
MTMasao Takemura
Masao Takemura
MOMichiko Osawa
Michiko Osawa
ASAki Sakurai
Aki Sakurai
KNKentaro Nakamoto
Kentaro Nakamoto
KSKuniaki Saito
Kuniaki Saito
Several immunochromatographic serological test kits have been developed to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies, but their relative performance and potential clinical utility is unclear. Three commercially available serological test kits were evaluated using 99 serum samples collected from 29 patients diagnosed with coronavirus disease 2019 (COVID-19) and 100 serum samples collected from 100 healthy volunteers in 2017 as negative controls. The specificity of the IgM and IgG antibodies showed comparable results among the three immunochromatographic serological test kits. The specificity for IgM antibody was 98.0%, 98.0%, and 97.0%, and the specificity for IgG antibody was identical among the three kits (99.0%). The IgM antibody-positive rates of the three test kits for samples taken at the early stage of the disease (0–4 days after onset) were consistent with all three kits (18.2%); however, the IgM antibody-positive rates thereafter showed considerable differences among the kits, making it difficult to interpret the kinetics of IgM response against SARS-CoV-2. The IgG antibody-positive rates for samples taken after 13 days of onset were 100.0%, 97.6%, and 97.6%, respectively. There were large differences among the results of the three test kits. Only few cases showed positive results for IgM, suggesting that at least 2 of these kits used in this study were unsuitable for diagnosis of COVID-19. The IgG antibody was positive in almost all samples after 13 days of onset, suggesting that it may be useful for determining infections in the recent past.